medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2017, Number 03

<< Back Next >>

Ginecol Obstet Mex 2017; 85 (03)

Myoinositol plus D-chiro-inositol: Preliminary results as first line management in PCOS

Carmona-Ruiz IO, Saucedo-de-la-Llata E, Moraga-Sánchez MR, Romeu-Sarrió A

Language: Spanish
References: 64
Page: 141-151
PDF size: 239.13 Kb.


ABSTRACT

Objetive: To assess the effect of a combined therapy with myoinositol (MI) and D-chiro-inositol (DCI) in Polycystic Ovary Syndrome (PCOS) patients.
Materials and Methods:An experimental, prospective, longitudinal study. It includes patients with PCOS diagnostic (by Rotterdam criteria) that have not received any form of therapy or management for the syndrome. All patients received an oral daily administration of MI and DCI for 90 days. Clinic and metabolic profiles are assessed pre and postreatment.
Results: Sixty-one patients are included and we observed an improvement in Ferriman-Gallwey scale (6.06 ± 2.0 y 5.57 ± 1.1; p=0.003, pre-and postreatment, respectively); left ovary volume (7.76 ± 3.2 y 7.18 ± 2.3; p=0.005, pre and postreatment, respectively). Left ovary antral follicle count (10.65 ± 6.4 y 10.20 ± 5.7; p=0.029, pre and postreatment, respectively) and right ovary antral follicle count (12.11 ± 6.5 y 11.75 ± 6.1, p=0.048, pre and postreatment, respectively). There is also an improvement in HOMA (1.85 ± 1.0 y 1.67 ± 0.7, p=0.015, pre and postreatment, respectively) and LH/FSH ratio (1.13 ± 0.8 y 0.99 ± 0.6, p=0.018 pre and post treatment, respectively).
Conclusion: We observed a positive effect with the combined administration of MI and DCI in clinic and metabolic profile of PCOS patients. Improvement in androgen profile, LH/FSH ratio and restoring menstrual cycles, may have a positive effect over the infertility caused by an anovulatory factor.


REFERENCES

  1. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health carerelated economic burden of the polycystic ovary syndrome during the reproductive life span. The Journal of Clinical Endocrinology and Metabolism. 2005;90(8):4650-8.

  2. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. The Journal of Clinical Endocrinology and Metabolism. 1999;84(6):1897-9.

  3. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. The Journal of Clinical Endocrinology and Metabolism 2006;91(1):2-6.

  4. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. Journal of Endocrinological Investigation. 2006;29(3):270-80.

  5. Amsterdam EA-SrPCWG. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Human Reproduction. 2012;27(1):14-24.

  6. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. The Journal of Clinical Endocrinology and Metabolism. 1998;83(9):3078-82.

  7. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar- Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. The Journal of Clinical Endocrinology and Metabolism. 2000;85(7):2434-8.

  8. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. The Journal of Clinical Endocrinology and Metabolism. 2004;89(6):2745-9.

  9. Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Human Reproduction. 2014.

  10. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clinical Endocrinology. 1999;51(6):779-86.

  11. Carmona-Ruiz IO, Saucedo-de la Llata E, Moraga-Sanchez MR, Romeu-Sarro A. [Polycystic ovary syndrome: is there a rise in the prevalence?]. Ginecol Obstet Mex. 2015;83(12):750-9.

  12. Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Seminars in Reproductive Endocrinology. 1997;15(2):111-22.

  13. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clinical Obstetrics and Gynecology. 2003;46(2):325-40.

  14. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertility and Sterility. 2004;81(1):114-9.

  15. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism: Clinical and Experimental. 1999;48(2):167-72.

  16. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecological endocrinology: the official Journal of the International Society of Gynecological Endocrinology. 2012;28(7):509-15.

  17. Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertility and Sterility. 2006;86 Suppl 1:S13-4.

  18. Pasquali R, Pelusi C, Ragazzini C, Hasanaj R, Gambineri A. Glucose tolerance, insulin secretion and insulin sensitivity in polycystic ovary syndrome. Journal of the Pancreas. 2002;3(1):1-7.

  19. Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecological Endocrinology 2007;23(3):146-52.

  20. Pasquali R, Gambineri A. Insulin-sensitizing agents in polycystic ovary syndrome. European journal of endocrinology / European Federation of Endocrine Societies. 2006;154(6):763-75.

  21. Huang LC, Fonteles MC, Houston DB, Zhang C, Larner J. Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocindiabetic rats in vivo. Endocrinology. 1993;132(2):652-7.

  22. Ma X, Fan L, Meng Y, Hou Z, Mao YD, Wang W, et al. Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Molecular Human Reproduction. 2007;13(8):527-35.

  23. Larner J. D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance. International Journal of Experimental Diabetes Research. 2002;3(1):47-60.

  24. Bevilacqua A, Bizzarri M. Physiological role and clinical utility of inositols in polycystic ovary syndrome. Best Practice & Research Clinical Obstetrics and Gynaecology. 2016.

  25. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertility and Sterility. 2004;81(1):19-25.

  26. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004;19(1):41-7.

  27. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Human Reproduction. 2011;26(11):3123-9.

  28. Hartshorne GM, Lilford RJ. Different perspectives of patients and health care professionals on the potential benefits and risks of blastocyst culture and multiple embryo transfer. Human Reproduction. 2002;17(4):1023-30.

  29. Nandi A, Chen Z, Patel R, Poretsky L. Polycystic ovary syndrome. Endocrinology and metabolism. Clinics of North America. 2014;43(1):123-47.

  30. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219-31.

  31. Semple RK. EJE PRIZE 2015: How does insulin resistance arise, and how does it cause disease? Human genetic lessons. Eur J Endocrinol. 2016;174(5):R209-23.

  32. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370(9588):685-97.

  33. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800.

  34. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends in Molecular Medicine. 2006;12(7):324-32.

  35. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertility and Sterility. 2000;73(6):1149-54.

  36. Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Human Reproduction. 2007;22(11):2967-73.

  37. Palomba S, Falbo A, Di Cello A, Cappiello F, Tolino A, Zullo F. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertility and Sterility. 2011;96(5):1128-33.

  38. Bourg CA, Phillips BB. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions. Ann Pharmacother. 2012;46(2):282-9.

  39. Bulletins--Gynecology ACoP. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol. 2009;114(4):936-49.

  40. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. The New England Journal of Medicine. 1999;340(17):1314-20.

  41. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2002;8(6):417-23.

  42. Cheang KI, Baillargeon JP, Essah PA, Ostlund RE, Jr., Apridonize T, Islam L, et al. Insulin-stimulated release of Dchiro- inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism: Clinical and Experimental. 2008;57(10):1390-7.

  43. Chiu TT, Tam PP. A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum. Journal of Assisted Reproduction and Genetics. 1992;9(6):524-30.

  44. Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Human Reproduction. 2002;17(6):1591-6.

  45. Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecological Endocrinology 2007;23(12):700-3.

  46. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11(5):347-54.

  47. Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. European Review for Medical and Pharmacological Sciences. 2009;13(2):105-10.

  48. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myoinositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecological Endocrinology 2008;24(3):139-44.

  49. Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertility and Sterility. 2009;91(5):1750-4.

  50. Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S. Myoinositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. European Review for Medical and Pharmacological Sciences. 2011;15(4):452-7.

  51. Harwood K, Vuguin P, DiMartino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Hormone Research. 2007;68(5):209- 17.

  52. Matalliotakis I, Kourtis A, Koukoura O, Panidis D. Polycystic ovary syndrome: etiology and pathogenesis. Archives of Gynecology and Obstetrics. 2006;274(4):187-97.

  53. Rice S, Christoforidis N, Gadd C, Nikolaou D, Seyani L, Donaldson A, et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Human Reproduction. 2005;20(2):373-81.

  54. Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertility and Sterility. 2011;95(8):2515-6.

  55. Chattopadhayay R, Ganesh A, Samanta J, Jana SK, Chakravarty BN, Chaudhury K. Effect of follicular fluid oxidative stress on meiotic spindle formation in infertile women with polycystic ovarian syndrome. Gynecologic and Obstetric Investigation. 2010;69(3):197-202.

  56. Isabella R, Raffone E. Does ovary need D-chiro-inositol? Journal of Ovarian Research. 2012;5(1):14.

  57. Galletta M, Grasso S, Vaiarelli A, Roseff SJ. Bye-bye chiroinositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction. European Review for Medical and Pharmacological Sciences. 2011;15(10):1212-4.

  58. Carlomagno G, De Grazia S, Unfer V, Manna F. Myoinositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert opinion on drug delivery. 2012;9(3):267-71.

  59. Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. European Review for Medical and Pharmacological Sciences. 2012;16(5):575-81.

  60. Lagana AS, Barbaro L, Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro- Inositol. Archives of Gynecology and Obstetrics. 2014.

  61. La Marca A, Grisendi V, Dondi G, Sighinolfi G, Cianci A. The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study. Gynecological Endocrinology 2014:1-5.

  62. Facchinetti F, Bizzarri M, Benvenga S, D'Anna R, Lanzone A, Soulage C, et al. Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. European journal of obstetrics, gynecology, and reproductive biology. 2015;195:72-6.

  63. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG : an international journal of obstetrics and gynaecology. 2006;113(10):1210-7.

  64. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171(4):P1-29.




2020     |     www.medigraphic.com